Default company panoramic image


Vatex is developing a hybrid medical device-IT system to combat the abuse and trafficking of prescription drugs- a healthcare epidemic.

  • Stage Product In Development
  • Industry Healthcare Services
  • Location Grapevine, TX, USA
  • Currency USD
  • Founded November 2010
  • Employees 2
  • Website

Company Summary

Vatex was formed to address the problem of prescription medication abuse. Vatex is developing Divert-X to monitor adherence to regimens for Controlled Substances. Patient compliance or behaviors consistent with abuse and trafficking will be established from real-time data of access to individual drug doses. Prescription drug misuse imposes a >$150 billion economic burden on US insurers- our customers. We will save lives and reduce costs.


  • Default avatar
    Simon Sellers

    Simon Sellers, PhD, MBA is the Vatex CEO. Simon has thirty years of experience in the chemical and biotech industries in both mid-size companies and start-ups. His expertise includes business strategy, new product introductions and corporate development.

  • Default avatar
    James Harris

    James Harris, PhD is the inventor of the concept being developed by Vatex. He is a former FDA staffer and the founder of a biopharmaceutical start-up. He is an expert in applying modern automated instrumentation methods to medical analysis. Jim has broad interests in seeking solutions to major healthcare challenges. Jim and Simon were both principals at Bioavailability Systems, LLC - a drug development start-up company.

Previous Investors

  • Default avatar
    Funded by management